Intermediate Repeats Confer Risk for Corticobasal Degeneration and Increase C 9 orf 72 Expression
暂无分享,去创建一个
G. Schellenberg | J. Trojanowski | D. Dickson | V. Lee | B. Ghetti | Eddie B. Lee | Jessica M. Phan | V. Deerlin | K. Mok | H. Ling | M. Patiño | Christopher P Cali
[1] F. Lamari,et al. New Antibody-Free Mass Spectrometry-Based Quantification Reveals That C9ORF72 Long Protein Isoform Is Reduced in the Frontal Cortex of Hexanucleotide-Repeat Expansion Carriers , 2018, Front. Neurosci..
[2] M. Oulad-Abdelghani,et al. Novel antibodies reveal presynaptic localization of C9orf72 protein and reduced protein levels in C9orf72 mutation carriers , 2018, Acta Neuropathologica Communications.
[3] Michael J. Cowan,et al. Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons , 2018, Nature Medicine.
[4] J. Trojanowski,et al. Pathological Tau Strains from Human Brains Recapitulate the Diversity of Tauopathies in Nontransgenic Mouse Brain , 2017, The Journal of Neuroscience.
[5] P. Gleeson,et al. C9ORF72, implicated in amytrophic lateral sclerosis and frontotemporal dementia, regulates endosomal trafficking , 2017, Human molecular genetics.
[6] M. Turner,et al. MN11 C9ORF72 and RAB7L1 regulate vesicle traffi cking in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia , 2017, Neuromuscular Disorders.
[7] L. Zon,et al. Loss-of-function mutations in the C9ORF72 mouse ortholog cause fatal autoimmune disease , 2016, Science Translational Medicine.
[8] A. Whitworth,et al. The C9orf72 protein interacts with Rab1a and the ULK1 complex to regulate initiation of autophagy , 2016, The EMBO journal.
[9] D. Borchelt,et al. C9orf72 BAC Mouse Model with Motor Deficits and Neurodegenerative Features of ALS/FTD , 2016, Neuron.
[10] D. Underhill,et al. C9orf72 is required for proper macrophage and microglial function in mice , 2016, Science.
[11] C. Broeckhoven,et al. The C9orf72 repeat size correlates with onset age of disease, DNA methylation and transcriptional downregulation of the promoter , 2015, Molecular Psychiatry.
[12] Murray Grossman,et al. Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy , 2015, Nature Communications.
[13] Kevin F. Bieniek,et al. C9ORF72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, and behavioral deficits , 2015, Science.
[14] J. Trojanowski,et al. Semi-automated quantification of C9orf72 expansion size reveals inverse correlation between hexanucleotide repeat number and disease duration in frontotemporal degeneration , 2015, Acta Neuropathologica.
[15] D. Maraganore,et al. Global investigation and meta-analysis of the C9orf72 (G4C2)n repeat in Parkinson disease , 2014, Neurology.
[16] Nigel J. Cairns,et al. Proteopathic tau seeding predicts tauopathy in vivo , 2014, Proceedings of the National Academy of Sciences.
[17] H. Morris,et al. Reduced C9orf72 protein levels in frontal cortex of amyotrophic lateral sclerosis and frontotemporal degeneration brain with the C9ORF72 hexanucleotide repeat expansion , 2014, Neurobiology of Aging.
[18] D. Irwin,et al. C9orf72 hypermethylation protects against repeat expansion-associated pathology in ALS/FTD , 2014, Acta Neuropathologica.
[19] T. Montine,et al. Absence of C9ORF72 expanded or intermediate repeats in autopsy‐confirmed Parkinson's disease , 2014, Movement disorders : official journal of the Movement Disorder Society.
[20] J. Ule,et al. Hexanucleotide Repeats in ALS/FTD Form Length-Dependent RNA Foci, Sequester RNA Binding Proteins, and Are Neurotoxic , 2013, Cell reports.
[21] L. Petrucelli,et al. Reduced C9orf72 gene expression in c9FTD/ALS is caused by histone trimethylation, an epigenetic event detectable in blood , 2013, Acta Neuropathologica.
[22] David A. Scott,et al. Genome engineering using the CRISPR-Cas9 system , 2013, Nature Protocols.
[23] L. Petrucelli,et al. Targeting RNA Foci in iPSC-Derived Motor Neurons from ALS Patients with a C9ORF72 Repeat Expansion , 2013, Science Translational Medicine.
[24] L. Petrucelli,et al. Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study , 2013, The Lancet Neurology.
[25] K. Xia,et al. C9orf72 mutation is rare in Alzheimer's disease, Parkinson's disease, and essential tremor in China , 2013, Front. Cell. Neurosci..
[26] Juan I. Young,et al. C9ORF72 Intermediate Repeat Copies Are a Significant Risk Factor for Parkinson Disease , 2013, Annals of human genetics.
[27] E. Rogaeva,et al. Hypermethylation of the CpG island near the G4C2 repeat in ALS with a C9orf72 expansion. , 2013, American journal of human genetics.
[28] C. Cruchaga,et al. Parkinson disease is not associated with C9ORF72 repeat expansions , 2013, Neurobiology of Aging.
[29] Ellen T. Gelfand,et al. The Genotype-Tissue Expression (GTEx) project , 2013, Nature Genetics.
[30] B. Traynor,et al. Screening for C9orf72 repeat expansions in parkinsonian syndromes , 2013, Neurobiology of Aging.
[31] Nick C Fox,et al. Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population. , 2013, American journal of human genetics.
[32] E. Haan,et al. C9ORF72 Repeat Expansion in Australian and Spanish Frontotemporal Dementia Patients , 2013, PloS one.
[33] Kevin F. Bieniek,et al. Unconventional Translation of C9ORF72 GGGGCC Expansion Generates Insoluble Polypeptides Specific to c9FTD/ALS , 2013, Neuron.
[34] J. Shih,et al. Analysis of the C9orf72 repeat in Parkinson's disease, essential tremor and restless legs syndrome. , 2013, Parkinsonism & related disorders.
[35] F. Pasquier,et al. C9orf72 repeat expansions are a rare genetic cause of parkinsonism. , 2013, Brain : a journal of neurology.
[36] Mark Hallett,et al. Criteria for the diagnosis of corticobasal degeneration , 2013, Neurology.
[37] P. Andersen,et al. No GGGGCC-hexanucleotide repeat expansion in C9ORF72 in parkinsonism patients in Sweden , 2013, Amyotrophic lateral sclerosis & frontotemporal degeneration.
[38] P. S. St George-Hyslop,et al. Investigation of c9orf72 in 4 neurodegenerative disorders. , 2012, Archives of neurology.
[39] F. Jessen,et al. A Pan-European Study of the C9orf72 Repeat Associated with FTLD: Geographic Prevalence, Genomic Instability, and Intermediate Repeats , 2012, Human mutation.
[40] F. J. Livesey,et al. Directed differentiation of human pluripotent stem cells to cerebral cortex neurons and neural networks , 2012, Nature Protocols.
[41] Janel O. Johnson,et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study , 2012, The Lancet Neurology.
[42] D. Neary,et al. Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. , 2012, Brain : a journal of neurology.
[43] M. Nalls,et al. The chromosome 9 ALS and FTD locus is probably derived from a single founder , 2012, Neurobiology of Aging.
[44] J. Trojanowski,et al. Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration , 2011, Nature Reviews Neuroscience.
[45] B. Boeve,et al. Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome. , 2011, Brain : a journal of neurology.
[46] David Heckerman,et al. A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD , 2011, Neuron.
[47] Pedagógia,et al. Cross Sectional Study , 2019 .
[48] John Q. Trojanowski,et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS , 2010, Nature.
[49] A. Lees,et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. , 2010, Brain : a journal of neurology.
[50] M. Tomishima,et al. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling , 2009, Nature Biotechnology.
[51] Lexin Li,et al. Elevated FMR1 mRNA in premutation carriers is due to increased transcription. , 2007, RNA.
[52] S. Sherman,et al. A study of the distributional characteristics of FMR1 transcript levels in 238 individuals , 2004, Human Genetics.
[53] P. Lantos,et al. Office of Rare Diseases Neuropathologic Criteria for Corticobasal Degeneration , 2002, Journal of neuropathology and experimental neurology.
[54] S. Warren,et al. Reduced FMRP and increased FMR1 transcription is proportionally associated with CGG repeat number in intermediate-length and premutation carriers. , 2001, Human molecular genetics.
[55] P. Hagerman,et al. Transcription of the FMR1 gene in individuals with fragile X syndrome. , 2000, American journal of medical genetics.
[56] R. Petersen,et al. Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia , 1999, Neurology.
[57] J. P. Brandel,et al. Accuracy of the Clinical Diagnosis of Corticobasal Degeneration , 1997, Neurology.
[58] S. Tsuji,et al. Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT , 1996, Nature Genetics.
[59] Ben A. Oostra,et al. Absence of expression of the FMR-1 gene in fragile X syndrome , 1991, Cell.
[60] J. Sutcliffe,et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome , 1991, Cell.
[61] C. Marks,et al. A Clinicopathologic Study , 2017 .
[62] J. A. Maguire,et al. Generation of human control iPS cell line CHOPWT10 from healthy adult peripheral blood mononuclear cells. , 2016, Stem cell research.
[63] D. Munoz. Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. , 2002, Neurology.